New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
News Oct 13, 2015
Barbara Burton, ’73 MD, ’75 ’77 GME, professor of Pediatrics in the Division of Genetics, Birth Defects and Metabolism, was the principal investigator for this study.
Currently, there are no safe or effective therapies for lysosomal acid lipase deficiency. Cholesterol-lowering medications have had limited success in reducing the progression of the disease and the eventual need for liver transplant.
A total of 66 patients were enrolled in the multi-center study, which was designed and supported by Synageva BioPharma, the pharmaceutical company that manufactures the drug. Patients were randomly assigned to receive either sebelipase alfa or a placebo for 20 weeks before entering the open-label period. The investigators evaluated the effectiveness of the therapy through the normalization of the alanine aminotransferase level (ALT), a test used to detect liver damage. They also looked at other disease-related symptoms and possible side effects.
“The enzyme replacement therapy appears to be effective in clearing fat from the liver of patients with this deficiency and normalizing their ALT,” said Dr. Burton, also a member of the Center for Genetic Medicineand the Stanley Manne Children’s Research Institute at the Ann & Robert H. Lurie Children’s Hospital of Chicago. “In many cases, we are hopeful this will prevent progression of the disease by reducing fat accumulation in the liver and prevent the need for liver transplantation.”
The clinical trial reported at 20 weeks that the ALT level was normal in 31 percent of patients in the sebelipase alfa group, and they observed improvements in lipid levels and reduction of fat content in the liver.
Dr. Burton is working on another clinical trial to evaluate this therapy in patients with more advanced disease.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018